Gates Foundation Trust’s Amgen AMGN Stock Holding History

Gates Foundation Trust’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-11,050	Closed	-$2.97M	–	28
2023 Q3	$2.97M	Buy	+11,050	New	+$2.76M	0.01%	46

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gates Foundation Trust's AMGN Position: Q4 2023 in Review

Gates Foundation Trust sold out of Amgen (AMGN) in Q4 2023, closing a stake of 11,050 shares — an estimated $2.97M sold.

Gates Foundation Trust first reported a position in AMGN in Q3 2023 and held it in 1 quarter. The position peaked at $2.97M in Q3 2023. 2,715 funds tracked by Wall St. Rank hold AMGN as of Q4 2023.

Gates Foundation Trust reported no remaining Amgen position as of Q4 2023 after selling out during the quarter.
Gates Foundation Trust sold 11,050 Amgen shares in Q4 2023, an estimated $2.97M.
Gates Foundation Trust first reported a position in Amgen in Q3 2023 and held it in 1 quarter.
Gates Foundation Trust's Amgen position peaked at $2.97M in Q3 2023.
2,715 funds tracked by Wall St. Rank held Amgen as of Q4 2023.

Based on Gates Foundation Trust's 13F filing for Q4 2023, filed 14 Feb 2024.